eFFECTOR Therapeutics (EFTRW) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Trading was temporarily halted for "EFTRW" at 08:04 AM with a stated reason of "News pending."April 4, 2024 | marketbeat.comeFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comeFFECTOR Therapeutics Inc. WarrantFebruary 4, 2024 | thestreet.comTrading was temporarily halted for "EFTRW" at 07:01 PM with a stated reason of "News pending."January 12, 2024 | marketbeat.comeFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024January 9, 2024 | finance.yahoo.comeFFECTOR updates Phase 1/2 data for breast cancer therapyDecember 8, 2023 | seekingalpha.comBuy Rating for eFFECTOR Therapeutics Backed by FDA Fast Track and Promising Clinical DataDecember 2, 2023 | markets.businessinsider.comeFFECTOR Therapeutics 10% owner SR One Capital Management discloses sale of 609,163 sharesNovember 30, 2023 | msn.comeFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerNovember 28, 2023 | finance.yahoo.comeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 27, 2023 | finanznachrichten.deeFFECTOR Therapeutics Stock (NASDAQ:EFTR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR) Dividends: History, Yield and DatesNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Inc.November 19, 2023 | thestreet.comeFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingNovember 15, 2023 | finance.yahoo.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceNovember 6, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid LeukemiaOctober 24, 2023 | finance.yahoo.com Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address Strange: Why is Amazon suddenly yielding 39.70%? (Ad)Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%! Click here to see this breakthrough before everyone else → EFTRW Media Mentions By Week EFTRW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EFTRW News Sentiment▼0.000.56▲Average Medical News Sentiment EFTRW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EFTRW Articles This Week▼00▲EFTRW Articles Average Week Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DRTSW News BCTXW News FBIOP News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EFTRW) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
